CIMZIA
Total Payments
$243,508
Transactions
10,421
Doctors
3,714
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3,720 | 1 | 1 |
| 2023 | $11,529 | 466 | 343 |
| 2022 | $82,401 | 4,591 | 2,286 |
| 2021 | $110,532 | 3,902 | 1,922 |
| 2020 | $22,460 | 1,443 | 842 |
| 2019 | $4,600 | 2 | 2 |
| 2018 | $8,235 | 14 | 4 |
| 2017 | $31.48 | 2 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $166,479 | 10,282 | 68.4% |
| Consulting Fee | $40,968 | 9 | 16.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,797 | 22 | 9.0% |
| Unspecified | $10,220 | 9 | 4.2% |
| Travel and Lodging | $2,886 | 17 | 1.2% |
| Education | $1,159 | 82 | 0.5% |
Payments by Type
General
$233,288
10,412 transactions
Research
$10,220
9 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients with Rheumatoid Arthritis | UCB, Inc. | $4,600 | 2 |
| PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN | UCB, Inc. | $2,300 | 1 |
| Phase 3, Multicenter, Randomized, Placebo-controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects with Active | UCB, Inc. | $1,640 | 2 |
| A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohns Disease | UCB, Inc. | $1,260 | 3 |
| Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis | UCB, Inc. | $420.00 | 1 |
Top Doctors Receiving Payments for CIMZIA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Gastroenterology | Charlotte, NC | $437.39 | 22 |
| , MD | Gastroenterology | Philadelphia, PA | $420.00 | 1 |
| Scott Lee | Gastroenterology | Seattle, WA | $420.00 | 1 |
| , M.D | Gastroenterology | Rochester, MN | $420.00 | 1 |
| , M.D | Specialist | New York, NY | $404.98 | 32 |
| James Sherman | — | Los Angeles, CA | $404.37 | 22 |
| , M.D | Gastroenterology | Chandler, AZ | $396.73 | 22 |
| , FNP | Nurse Practitioner | Charlotte, NC | $364.00 | 2 |
| , M.D., | Gastroenterology | Scottsdale, AZ | $358.16 | 20 |
| , M.D | Gastroenterology | New York, NY | $358.16 | 26 |
| , MD | Gastroenterology | Lansdowne, VA | $351.27 | 36 |
| , MD | Gastroenterology | New York, NY | $348.75 | 38 |
| Ellie Gonyeau | Family | Boston, MA | $347.39 | 12 |
| , M.D | Gastroenterology | New York, NY | $346.81 | 33 |
| , MD | Gastroenterology | New York, NY | $344.38 | 37 |
| , M.D | Gastroenterology | Chandler, AZ | $343.65 | 20 |
| , M.D., | Gastroenterology | Scottsdale, AZ | $339.15 | 19 |
| , MD | Gastroenterology | Louisville, KY | $338.97 | 15 |
| , M.D | Gastroenterology | Frederick, MD | $333.54 | 30 |
| , M.D | Gastroenterology | Miami, FL | $328.66 | 24 |
| , M.D | Gastroenterology | New York, NY | $328.46 | 24 |
| , C.N.P | Adult Health | Canton, OH | $316.43 | 47 |
| , NP | Family | Leesburg, VA | $311.85 | 36 |
| , M.D | Gastroenterology | Huntington, NY | $304.77 | 15 |
| , M.D | Gastroenterology | Chandler, AZ | $302.48 | 17 |
Ad
Manufacturing Companies
- Ferring Pharmaceuticals Inc. $224,985
- UCB, Inc. $18,425
- UCB Biosciences Inc. $98.84
Product Information
- Type Drug
- Total Payments $243,508
- Total Doctors 3,714
- Transactions 10,421
About CIMZIA
CIMZIA is a drug associated with $243,508 in payments to 3,714 healthcare providers, recorded across 10,421 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals Inc..
Payment data is available from 2017 to 2024. In 2024, $3,720 was paid across 1 transactions to 1 doctors.
The most common payment nature for CIMZIA is "Food and Beverage" ($166,479, 68.4% of total).
CIMZIA is associated with 5 research studies, including "Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients with Rheumatoid Arthritis" ($4,600).